Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLD: Trastuzumab Duration in Early Breast Cancer
NCT00593697Phase 3Completed
- Sponsor
- Finnish Breast Cancer Group
- Start
- Jan 2008
- Primary completion
- Nov 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Finnish Breast Cancer Group. Started Jan 2008; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00593697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593697.